Biotech and Pharmaceuticals Pharmaceuticals

More

  • Now Chantix maker Pfizer and Zyban maker GlaxoSmithKline hope the Food and Drug Administration, which ordered them to do the study, will remove the so-called "black box warnings" put on their prescription drugs due to anecdotal patient reports of serious psychiatric side effects. Zyban, approved in 1997, has been available as generic bupropion for a decade, so...

  • Now Chantix maker Pfizer and Zyban maker GlaxoSmithKline hope the Food and Drug Administration, which ordered them to do the study, will remove the so-called "black box warnings" put on their prescription drugs due to anecdotal patient reports of serious psychiatric side effects. Zyban, approved in 1997, has been available as generic bupropion for a decade, so...

  • Valeant said on Friday it had until June 21 to file the report under its bond agreements, but reiterated its intention to file it on or before April 29. The Quebec- based drugmaker said last week it had received a notice of default from its bondholders. Valeant has said it risked defaulting on its $30 billion debt if it missed the April 29 deadline.

  • Traders work on the floor of the New York Stock Exchange underneath a board showing the name of Valeant Pharmaceuticals shortly before the opening of the markets in New York October 22, 2015.

    Valeant's spike is justified if reports about the company's possible leadership change are true.

  • Joseph Papa, CEO of Perrigo.

    Drugmaker Valeant Pharmaceuticals is seeking to appoint Perrigo boss Joseph Papa as its new chief executive, a source familiar with the matter said.

  • NEW YORK— The over-the-counter drugmaker Perrigo says it's aware of media reports that its CEO will take the top job at troubled Valeant Pharmaceuticals, but it won't confirm those reports. The Wall Street Journal reported Thursday that Valeant is finalizing a contract with Perrigo Chairman and CEO Joseph C. Papa and could announced the hire as early as next...

  • April 21- Drugmaker Valeant Pharmaceuticals International Inc is seeking to appoint Perrigo Co Plc's boss Joseph Papa as its new chief executive, a source familiar with the matter said. The Wall Street Journal earlier reported that Valeant was looking to name Papa as next CEO. Valeant said in March CEO Michael Pearson was leaving the company, just three weeks...

  • A customer shops inside a Walgreens

    Walgreen agreed to remove stale shelf tags within 36 hours and end the use of "last chance" or "clearance" tags to promote items that are neither.

  • Sarepta shares plummet after negative FDA outlook

    Sarepta Therapeutics has been trying to win accelerated approval for a drug to treat Duchenne muscular dystrophy.

  • ZURICH, April 21- Novartis Chief Executive Joe Jimenez said on Thursday bribery allegations against the drugmaker were legacy issues and it had set aside enough money to cover any penalties. The drugmaker has disputed the allegations, which were filed in 2013, but now faces an investigation in Turkey after an anonymous whistleblower alleged it paid bribes...

  • Novartis profits hurt from generic drug competition

    The Swiss pharmaceutical company struggles after a cheaper version of Gleevec launched in February.

  • GENEVA— Swiss pharmaceuticals maker Novartis says net income from continued operations fell 13 percent in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines. Novartis noted the start of sales of a U.S. generic version of Gleevec— which had cost around $10,000 per month— in February.

  • HOUSTON— The U.S. Food and Drug Administration is refusing to back down from its decision to block the Texas prison system from importing a drug that could be used for capital punishment in the state that carries out the most executions in the nation. The decision from the FDA comes after the Texas Department of Criminal Justice had appealed the federal agency's...

  • Sanofi reported a meager $10 million from Praluent in the last quarter, which it co-markets with Regeneron Pharmaceuticals. Amgen Inc. declined to break out Repatha sales. Spending on pricey specialty drugs has doubled over the last five years to $150 billion, contributing 70 percent of the growth in U.S. medication spending since 2010, according to IMS...

  • 'Pot stock' flying high this year

    GW Pharmaceuticals stock has risen more than 20 percent to outperform the broader markets.

  • Opioid abuse is costing US companies

    Large employers are losing $10 billion each year due to the explosion of opioid abuse in the US.

  • April 19- Johnson& Johnson beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar, and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year. J&J shares rose as much as 2.7 percent to an all-time high of $113.95. But investors have been concerned it could be...

  • Shares of J&J, the maker of Band-Aids and Tylenol, rose slightly to $111.50 in premarket trading. Pharmaceutical sales rose 5.9 percent to $8.2 billion in the first quarter, helped by growing demand for the Imbruvica cancer drug, Xarelto blood clot preventer and Invokana treatment for diabetes. Net earnings fell to $4.29 billion, or $1.54 per share, from $4.32...

  • *Q1 sales rise to 12.4 bln Sfr vs 12.3 bln Sfr in poll. ZURICH, April 19- Roche sales in the first three months of the year beat analyst forecasts, setting a pace that Swiss local rival Novartis and others in the drug industry could struggle to match. Analysts also cited flu drug Tamiflu as a big reason why Roche beat forecasts, as sales hit 367 million francs, more than 100...

  • Roche reiterated on Tuesday that it expects to achieve its full-year targets after sales during the first three months of 2016 rose 4 percent.